N-dihydrogalactochitosan clinical trials
Also written IP-001.
How each study uses N-dihydrogalactochitosan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the N-dihydrogalactochitosan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 4
Immunophotonics, Inc. (2) · Robert C. Martin (2) · Swiss Cancer Institute (1) · M.R. Meijerink (1)
Studies
Open first, then newest update. How each study uses N-dihydrogalactochitosan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Immunotherapy and Irreversible Electroporation (IRE) in the Treatment of Locally Advanced Pancreatic AdenocarcinomaNot yet recruitingPhase 1Robert C. MartinNCT07930936Written as 1.0% IP-001 for injection
- Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation AloneRecruitingPhase 2Robert C. MartinNCT06526338Written as 1.0% IP-001 for injection
- Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver MetastasesNot yet recruitingPhase 2/3Immunophotonics, Inc.NCT07321847Written as 1.0% IP-001 for Injection, a 10 mg/mL solution of IP-001 in water
- Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLMRecruitingPhase 1/2M.R. MeijerinkNCT06630624Written as IP-001
- Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.CompletedPhase 1/2Swiss Cancer InstituteNCT03993678Written as IP-001
- Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STSActive, not recruitingPhase 1/2Immunophotonics, Inc.NCT05688280Written as 1.0% IP-001 for Injection
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call N-dihydrogalactochitosan · ClinicalTrials.gg INT001687
- MeSH (NLM) C000718712N-dihydrogalactochitosanOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718712 | N-dihydrogalactochitosan | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.